Free Trial

Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low - What's Next?

Structure Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Structure Therapeutics hit a new 52-week low, trading as low as $18.68 after closing previously at $20.00; its 50-day and 200-day moving averages were $27.88 and $46.06, respectively.
  • The company reported a quarterly loss of $0.66 per share, missing analysts’ expected loss of $0.51. HC Wainwright kept its Buy rating but lowered forecasts and expects losses to continue through FY2030.
  • Analyst sentiment remains broadly positive: MarketBeat lists a “Moderate Buy” consensus and a $110.91 average price target, while institutional investors own 91.78% of shares.
  • Interested in Structure Therapeutics? Here are five stocks we like better.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) reached a new 52-week low during mid-day trading on Monday. The company traded as low as $18.68 and last traded at $18.5670, with a volume of 196,905 shares traded. The stock had previously closed at $20.00.

More Structure Therapeutics News

Here's some of the latest news about GPCR:

  • Positive Sentiment: HC Wainwright retained its Buy rating, signaling continued confidence despite revising estimates. Structure Therapeutics analyst coverage
  • Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $2.18 per share from $1.84, and reduced its Q4 2026 estimate to a loss of $0.68 from $0.50. The analyst also projects annual losses through FY2030, including $2.40 per share in FY2027. These lower estimates point to higher expected losses and are the clearest negative catalyst in the recent reports. HC Wainwright FY2026 earnings opinion

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GPCR. Citizens Jmp reiterated a "market outperform" rating and issued a $110.00 target price on shares of Structure Therapeutics in a research note on Wednesday, September 9th. HC Wainwright restated a "buy" rating on shares of Structure Therapeutics in a research note on Thursday. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings upgraded Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Finally, Citigroup reissued a "market outperform" rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $110.91.

Check Out Our Latest Analysis on GPCR

Structure Therapeutics Price Performance

The firm's 50 day moving average price is $27.88 and its two-hundred day moving average price is $46.06. The stock has a market cap of $1.30 billion, a PE ratio of -14.52 and a beta of -1.12.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). Analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -2.10 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GPCR. IFP Advisors Inc purchased a new stake in shares of Structure Therapeutics in the second quarter worth $46,000. Assetmark Inc. grew its stake in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after buying an additional 449 shares during the last quarter. Sterling Capital Management LLC increased its stake in Structure Therapeutics by 63.6% in the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company's stock worth $105,000 after purchasing an additional 1,300 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Structure Therapeutics in the third quarter worth $132,000. Finally, Cetera Investment Advisers raised its stake in shares of Structure Therapeutics by 17.0% during the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company's stock valued at $372,000 after acquiring an additional 1,124 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company's pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines